|

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

RECRUITINGSponsored by CHA University
Actively Recruiting
SponsorCHA University
Started2024-09-23
Est. completion2026-09-23
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06648057

Summary

The goal of this observational study is to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in patients with advanced biliary tract cancer (BTC). This study aims to identify potential biomarkers that may predict treatment response by analyzing genetic data from blood and tissue samples. The study will focus on real-world clinical outcomes and the exploratory discovery of biomarkers associated with the efficacy of this treatment regimen.

Eligibility

Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with histologically or cytologically confirmed advanced biliary tract cancer.
* Patients scheduled to receive Lenvatinib + Pembrolizumab for the treatment of advanced biliary tract cancer.
* ECOG performance status of 0-2.
* Patients aged 20 years or older at the time of treatment initiation.
* Patients who understand and consent to participate in this study, and agree to provide samples obtained during the examination process.

Exclusion Criteria:

* Patients who do not consent to participate in the study or withdraw their consent.

Conditions3

Biliary Tract CancerCancerCholangiocarcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.